Judith Abrams, Ph.D.
87 E. Canfield Street, Suite
Detroit, MI 48201
- Application of biostatistical methods to cancer research projects
- Assessment of new biostatistical methods for applicability to cancer research projects
I collaborate with cancer research investigators on the design and analysis of their projects.
Rosner K, Mehregan DR, Kirou E, Abrams J, Kim S, Campbell M, Frieder J, Lawrence K, Haynes B, Shekhar MP. Melanoma Development and Progression Are Associated with Rad6 Upregulation and β -Catenin Relocation to the Cell Membrane. J Skin Cancer. 2014;2014:439205.
Bhutani D, Zonder J, Valent J, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Lum L, Ratanatharathorn V, Uberti J, Abidi MH. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma. Support Care Cancer. 2013;21:2437-42.
Sosin AM, Burger AM, Siddiqi A, Abrams J, Mohammad RM, Al-Katib AM.HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. J Hematol Oncol. 2012;5:57.
Abidi MH, Agarwal R, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Ratanatharathorn V, Zonder J, Uberti J. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant. 2013;19:56-61.
Abidi MH, Gul Z, Abrams J, Ayash L, Deol A, Ventimiglia M, Lum L, Mellon-Reppen S, Al-Kadhimi Z, Ratanatharathorn V, Zonder J, Uberti J. Phase I trial of bortezomib during maintenance phase after high dose melphalan and autologous stem cell transplantation in patients with multiple myeloma. J Chemother. 2012;24:167-72.
Wang G, Liu G, Wang X, Sethi S, Ali-Fehmi R, Abrams J, Zheng Z, Zhang K, Ethier S, Yang ZQ. ERLIN2 promotes breast cancer cell survival by modulating endoplasmic reticulum stress pathways. BMC Cancer. 2012 ;12:225.
Abidi MH, Agarwal R, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Zonder J, Ratanatharathorn V, Uberti J.Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial. Biol Blood Marrow Transplant. 2012;18:1455-61.
Piechocki MP, Wu GS, Jones RF, Jacob JB, Gibson H, Ethier SP, Abrams J, Yagita H, Venuprasad K, Wei WZ. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. Int J Cancer. 2012;131:2562-72.
Abidi MH, Tageja N, Ayash L, Abrams J, Ratanatharathorn V, Al-Kadhimi Z, Lum L, Cronin S, Ventimiglia M, Uberti J. Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial. Support Care Cancer. 2012;20:2363-9.
Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P, Lorusso PM. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat. 2012;131:933-7.
Education and Training:
AB (1965): St. John’s College, Annapolis, Maryland
MS in Biochemistry (1973): University of Vermont, Burlington, Vermont
MS in Computer Science (1978): New York University, New York, New York
PhD in Biostatistics (1984): University of Michigan, Ann Arbor, Michigan
Cancer Biology Courses Taught:
CB7300 Special Topics F31 Grant Writing Course
CB7990 Research Technologies in Cancer Research